title: Invasive aspergillosis associated with bevacizumab, a vascular endothelial growth factor inhibitor.
authors.forename: John
authors.initials: J
authors.lastname: Williams
authors.forename: Robert
authors.initials: R
authors.lastname: Lim
authors.forename: Paul
authors.initials: P
authors.lastname: Tambyah
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000139:chemically induced* / Q000188:drug therapy; D000068258:Bevacizumab; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D000068258:Bevacizumab; D017964:Itraconazole; D000666:Amphotericin B